
Plumbing Manufacturers International's Annual Report Shows That Finding Common Ground is the Smartest Strategy
'Everything we do ultimately leads back to our vision of safe, responsible plumbing—always,' stated PMI CEO/Executive Director Kerry Stackpole. 'PMI always endeavors to find the common ground that balances the concerns of all stakeholders."
This role as mediator is not new to PMI or its members. Over the years, the plumbing manufacturing Industry has learned that participating in the debate is more productive than fighting or fleeing it. The industry's responsibility to customers, business partners, and its companies is to stay relevant, trustworthy, and in the room where decisions happen.
'Everything we do ultimately leads back to our vision of safe, responsible plumbing—always,' stated PMI CEO/Executive Director Kerry Stackpole. 'PMI always endeavors to find the common ground that balances the concerns of all stakeholders, whether that's in relation to trade policy, water management, workplace issues, sustainability, or public health and safety. We have found that the best solutions, the ones that stand the test of time, have broad support.'
PMI first began establishing this business posture when the debates leading up to the Energy Policy Act (EPAct) of 1994 and the establishment of the WaterSense program in 2006 were occurring. At these key moments in plumbing manufacturing history, PMI and its members realized that, by contributing to solutions rather than by being simply opposed to proposed actions, they would be valuable to the powers that be. By gaining a seat at the table while the EPAct and WaterSense were being developed, PMI and its members helped to establish harmonized federal water-efficiency standards and specifications and mitigated the adverse effects created by the patchwork of state regulations.
Today, as those standards and specifications are called into question and our industry grapples with the inflationary effects of tariffs, PMI again finds itself at a crossroads—whether to oppose what is happening or to participate in the process of finding a sensible common ground. PMI chooses to be proactive and find common ground.
This year's annual report again demonstrates the ability of PMI and its members to develop sensible and valuable solutions to many of the challenges facing our society, no matter what the government policies are. PMI members continue to build bridges to prosperity through free trade, to make water a sustainable resource, to foster productive and diverse workplaces, to extend innovation into all aspects of business operations, and to fulfill public health and safety responsibilities.
By contributing scientific data and common sense to all discussions, the plumbing manufacturing industry has earned a reputation among federal and state policymakers, peer industry groups, and the media as a credible and trustworthy voice. The examples in this report bear this out.
Read the 2025 PMI Annual Report: safeplumbing.org/2025annualreport
About Plumbing Manufacturers International
Plumbing Manufacturers International (PMI) is the trade association of plumbing product manufacturers that produce more than 90% of the United States' plumbing products, represent more than 150 iconic brands, and develop safe, reliable and innovative water-efficient plumbing technologies. PMI members contribute 517,696 jobs and $116.7 billion in economic impact to America's economy, according to the Plumbing Manufacturing Industry Economic Impact Study.
With a vision of safe, responsible plumbing – always, PMI advocates for plumbing product performance contributing to water efficiency and savings, sustainability, public health and safety, and consumer satisfaction through its Rethink Water initiative and other programs. PMI members manufacture water-efficient toilets, urinals, faucets, showerheads and other products at more than 70 locations across the country and market them online and in more than 26,000 home improvement stores, hardware stores and showrooms in all 50 states. For more information on PMI, contact the organization at 1750 Tysons Blvd., Ste. 1500, McLean, Va., 22102; tel.: 847-481-5500; fax: 847-481-5501. safeplumbing.org.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Euro zone business growth inched up in July but remained subdued, PMI shows
LONDON (Reuters) -Business activity in the euro zone grew at a slightly faster pace in July than in June but remained sluggish as demand dipped, a survey showed on Tuesday. The HCOB Eurozone Composite Purchasing Managers' Index, compiled by S&P Global, edged up to 50.9 in July from 50.6 in June, just below a preliminary estimate of 51.0. PMI readings above 50.0 indicate growth in activity while those below point to a contraction. July's reading marked a four-month high but was still below the survey's long-term average of 52.4, reflecting persistent weakness in the 20-country currency bloc. Services activity expanded at a slightly faster rate with the sector's PMI climbing to 51.0 from 50.5 in June. "This could turn out to be a good summer for service providers. In Italy and Spain, business activity rose more sharply in July than in the previous month, while Germany, after several challenging months, has clawed its way back into growth territory," said Cyrus de la Rubia, chief economist at Hamburg Commercial Bank. Overall new orders remained virtually unchanged, continuing a trend seen in June, while export sales contracted for the 41st consecutive month, acting as a persistent drag on growth. The composite new business index nudged up to 49.8 from 49.7. Among the bloc's largest economies, Spain led the way with the strongest expansion, followed by Italy. Germany, the region's biggest economy, recorded only modest growth, however. France was the only major euro zone economy to contract, with its PMI falling from the previous month, marking the 11th straight month of decline. Despite sluggish demand, the bloc's firms added jobs for a fifth consecutive month in July. The pace of job creation, while still modest, reached its fastest rate in over a year. Business confidence dipped for the first time since April, falling further below its long-term average as sentiment weakened across both manufacturing and services sectors. Cost pressures eased to their lowest level since October last year, primarily driven by the services sector, while output price inflation increased marginally to a three-month high. The services input prices index fell to 56.5 from 58.1. "Inflation is easing in the euro zone's services sector, increasing the likelihood of one further interest rate cut by the European Central Bank in the second half of the year," de la Rubia added. The ECB left interest rates unchanged in July but is expected to make one further cut this year, according to a July Reuters poll. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Data Sovereignty Shapes Netherlands Cloud Strategies
Enterprises adopt hybrid and multicloud architectures for data protection, flexibility, edge computing, ISG Provider Lens® report says AMSTERDAM, August 05, 2025--(BUSINESS WIRE)--Enterprises in the Netherlands are shifting to hybrid and multicloud environments for agility, security and compliance, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands finds demand for sovereign cloud solutions rising as data protection and digital sovereignty mandates grow stricter and more coordinated. Dutch enterprises, particularly in regulated sectors such as healthcare, finance and government, are seeking cloud architectures that ensure sensitive data remains within national boundaries. "The Dutch market is experiencing rapid growth in sovereign and hybrid cloud adoption," said Anthony Drake, partner at ISG. "This trend aligns closely with sustainability initiatives that are also influencing data center investments." The Netherlands is emerging as a leading European market for colocation and edge computing, driven by enterprise demand for secure, sustainable and compliant data centers, the report says. As edge computing grows, many organizations are also using colocation centers for faster data processing that is available closer to users. Sustainability goals are driving Dutch enterprises toward green data center operations, with more than 80 percent of centers already powered by renewable energy, ISG says. Enterprises adopt measures such as advanced cooling technologies, waste heat reuse and renewable energy integration to enhance operational efficiency, comply with environmental laws and meet national climate targets. Many Dutch companies are adopting advanced technologies such as AI, ML and real-time monitoring to strengthen cloud operations and security, the report says. Industries including healthcare and finance embrace robust security models such as zero trust to protect complex cloud environments. Amid this evolution, providers are addressing skills shortages by expanding managed services and automation, helping clients address cloud complexity. Enterprises in the Netherlands increasingly seek flexible, customized cloud solutions that go beyond basic infrastructure to support efficient workload migration, seamless integration and enhanced security for sensitive data, ISG says. Companies need these environments to ensure greater operational control, improved performance and adherence to evolving data protection regulations. "Dutch enterprises are prioritizing adaptable cloud strategies to navigate changing technology demands," said Meenakshi Srivastava, lead analyst, ISG Provider Lens Research, and lead author of the report. "They prefer tailored services that simplify compliance while providing strong protection." The report also explores other cloud trends in the Netherlands, including the requirement for cloud portability and interoperability to avoid vendor lock-in and the deployment of adaptive AI solutions to streamline complex business processes. For more insights into the cloud-related challenges faced by Dutch enterprises, along with ISG's advice for addressing them, see the ISG Provider Lens® Focal Points briefing here. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands evaluates the capabilities of 48 providers across three quadrants: Managed Services, Colocation Services and AI-Ready Infrastructure Consulting. The report names Accenture, Capgemini, Kyndryl and TCS as Leaders in two quadrants each. Atos, Cognizant, CyrusOne, Digital Realty, DXC Technology, Equinix, Eurofiber Cloud Infra, maincubes, NorthC Datacenters, NTT DATA, QTS and Wipro are named as Leaders in one quadrant each. In addition, LTIMindtree and nLighten are named as Rising Stars — companies with a "promising portfolio" and "high future potential" by ISG's definition — in one quadrant each. In the area of customer experience, Persistent Systems is named the global ISG CX Star Performer for 2025 among private/hybrid cloud and data center service providers. Persistent Systems earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry. The 2025 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Netherlands is available to subscribers or for one-time purchase on this webpage. About ISG Provider Lens® Research The ISG Provider Lens® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments. View source version on Contacts Press Contacts: Laura Hupprich, ISG+1 203 517 Philipp Jaensch, ISG+49 151 730 365 Sign in to access your portfolio


Business Wire
26 minutes ago
- Business Wire
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland--(BUSINESS WIRE)--Polpharma Biologics S.A. ('Polpharma Biologics') announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. 'This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally,' said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. 'Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.' The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. *Entyvio® is a registered trademark of Takeda. About Polpharma Biologics: Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Learn more at About Fresenius Kabi: As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Important Note This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Disclaimer This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy.